Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck

Reforms to the Waxman/Hatch patent extension program should focus on "clarification" of patent life, rather than "fundamental changes" to the generic drug approval and extension process, Merck Senior Director-Government Relations Ian Spatz told the National Institute for Health Care Management Sept. 25 in Washington, D.C.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet